Fig. 2: New exonic donor site-activating SF3B4 mutation targeted by YSC-001 via three different chemistries.

a YSC-001 is specifically designed to target the new donor site, preventing the activation of the new intron. The gel image shows the wild-type and aberrant transcripts in the wild-type minigene, mutant minigene, mutant minigene following standard morpholino treatment (40 µM), and mutant minigene following control morpholino treatment (40 µM). b The gel image shows the effects of standard morpholino at different concentrations on the wild-type and aberrant transcripts of the mutant minigene. The graph compares the wild-type and aberrant transcript expression levels of the mutant minigene following ASO treatment to those of the wild-type minigene. c The gel image shows the effects of different concentrations of Vivo-morpholino on the wild-type and aberrant transcripts of the mutant minigene. The graph compares the wild-type and aberrant transcript expression levels of the mutant minigene following ASO treatment to those of the wild-type minigene. d The gel image shows the effects of 2′MOE at different concentrations on the wild-type and aberrant transcripts of the mutant minigene. The graph compares the wild-type and aberrant transcript expression levels of the mutant minigene following ASO treatment to those of the wild-type minigene. e The summary table presents the outcomes of three different types of ASOs with varying chemistries.